| Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis F Liu, D Lagares, KM Choi, L Stopfer, A Marinković, V Vrbanac, CK Probst, ... American Journal of Physiology-Lung Cellular and Molecular Physiology 308 (4 …, 2015 | 821 | 2015 |
| Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition LE Stopfer, JM Mesfin, BA Joughin, DA Lauffenburger, FM White Nature Communications 11 (1), 2760, 2020 | 84 | 2020 |
| Deciphering the immunopeptidome in vivo reveals new tumour antigens AM Jaeger, LE Stopfer, R Ahn, EA Sanders, DA Sandel, WA Freed-Pastor, ... Nature 607 (7917), 149-155, 2022 | 69 | 2022 |
| High-density, targeted monitoring of tyrosine phosphorylation reveals activated signaling networks in human tumors LE Stopfer, CT Flower, AS Gajadhar, B Patel, S Gallien, D Lopez-Ferrer, ... Cancer Research 81 (9), 2495-2509, 2021 | 60 | 2021 |
| Rebalancing protein homeostasis enhances tumor antigen presentation AM Jaeger, L Stopfer, S Lee, G Gaglia, D Sandel, S Santagata, NU Lin, ... Clinical Cancer Research 25 (21), 6392-6405, 2019 | 46 | 2019 |
| Microtubule-based control of motor-clutch system mechanics in glioma cell migration LS Prahl, PF Bangasser, LE Stopfer, M Hemmat, FM White, SS Rosenfeld, ... Cell reports 25 (9), 2591-2604. e8, 2018 | 46 | 2018 |
| Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants LE Stopfer, AS Gajadhar, B Patel, S Gallien, DT Frederick, GM Boland, ... Proceedings of the National Academy of Sciences 118 (37), e2111173118, 2021 | 35 | 2021 |
| Quantitative consequences of protein carriers in immunopeptidomics and tyrosine phosphorylation MS2 analyses LE Stopfer, JE Conage-Pough, FM White Molecular & Cellular Proteomics 20, 2021 | 31 | 2021 |
| 1, 2, 3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs LE Stopfer, AD D'Souza, FM White Immuno-Oncology and Technology 11, 100042, 2021 | 21 | 2021 |
| Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma RS Kenchappa, A Dovas, MG Argenziano, CT Meyer, LE Stopfer, ... Cell reports 39 (12), 2022 | 18 | 2022 |
| MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas LE Stopfer, NJ Rettko, O Leddy, JM Mesfin, E Brown, S Winski, B Bryson, ... Proceedings of the National Academy of Sciences 119 (49), e2208900119, 2022 | 17 | 2022 |
| A simplified culture system to examine soluble factor interactions between mammalian cells MJ Carroll, LE Stopfer, PK Kreeger Chemical Communications 50 (40), 5279-5281, 2014 | 17 | 2014 |
| Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins TB Fessenden, LE Stopfer, F Chatterjee, J Zulueta, J Mesfin, TC Dumit, ... Journal for ImmunoTherapy of Cancer 10 (7), e004159, 2022 | 11 | 2022 |
| Fabric force sensors for the clinical breast examination simulator S Laufer, K Rasske, L Stopfer, C Kurzynski, T Abbott, M Platner, J Towles, ... Medicine Meets Virtual Reality 22, 193-198, 2016 | 7 | 2016 |
| Functional genomics approach identifies novel signaling regulators of TGFα ectodomain shedding JL Wilson, E Kefaloyianni, L Stopfer, C Harrison, VS Sabbisetti, ... Molecular Cancer Research 16 (1), 147-161, 2018 | 5 | 2018 |
| Deciphering the tumor-specific immunopeptidome in vivo with genetically engineered mouse models AM Jaeger, LE Stopfer, EA Sanders, DA Sandel, WA Freed-Pastor, ... bioRxiv, 2021.06. 30.450516, 2021 | 3 | 2021 |
| Pharmaceutical compositions for delivery of viral antigens and related methods RB Gaynor, MS Rooney, A Poran, T Addona, S Goulding, E Esaulova, ... US Patent App. 18/701,119, 2024 | | 2024 |
| Validation and quantification of peptide antigens presented on MHCs using SureQuant O Leddy, Y Cui, R Ahn, L Stopfer, E Choe, DH Kim, M Roerden, ... Nature Protocols, 1-27, 2024 | | 2024 |
| Tissue-specific antigens for cancer immunotherapy MS Rooney, LE Stopfer US Patent App. 18/334,820, 2024 | | 2024 |
| DDDR-28. EGFR AND SRC-MEDIATED ACTIVATION OF STAT3 DRIVES RESISTANCE TO MITOTIC INHIBITORS IN GLIOBLASTOMA, AND CAN BE REVERSED WITH FDA-APPROVED DRUGS R Kenchappa, A Dovas, M Argenziano, C Meyer, L Stopfer, M Banu, ... Neuro-Oncology 24 (Supplement_7), vii105-vii105, 2022 | | 2022 |